Q32 Bio (QTTB) announced that the FDA has granted Fast Track designation to Q32 Bio’s bempikibart for the treatment of AA. Bempikibart is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling that is in development for the treatment of AA and currently being evaluated in a Phase 2 program.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTTB:
- Q32 Bio Board Member Mark Iwicki Resigns
- Q32 Bio doses first patient in both parts of SIGNAL-AA trial
- Q32 Bio price target lowered to $15 from $16 at Wells Fargo
- Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures
- Q32 Bio Reports Promising Trial Results and Financials